Clinical trials: Cytomegalovirus Cell Mediated Immunity
Kidney Transplant Infection
Randomized Clinical Trial, Open, Multicenter Parallel, no Suspension Inferiority Prophylactic Treatment With Valganciclovir in Kidney Transplant CMV-seropositive Cellular Immunity to Develop CD8 + CMV-specific Treatment After Induction Thymoglobulin.
Hypothesis: Valganciclovir prophylaxis can be discontinued before 3 months in CMV-seropositive renal transplant recipients receiving induction thymoglobulin when developing CMV-specific cellular immunity after transplantation.
- Trial name
- NCT03123627
- Testing
- New profilaxis, Profilaxis recommended
- Where
- Spain
- Volunteers
- 150 people
- Sponsor
- Maimónides Biomedical Research Institute of Córdoba
Atherosclerosis, Chlamydia Infections
Effects of Hormone Therapy on the Immune Systems of Postmenopausal Women With Chronic Infections
Hardening of the arteries (atherosclerosis) and heart disease are much more common in men than in women. However, as women grow older, especially after menopause the incidence of atherosclerosis and heart disease increases.
- Conditions
- Atherosclerosis, Chlamydia Infections, Cytomegalovirus Infections, Pneumonia, Bacterial
- Trial name
- NCT00001890
- Testing
- Estrogen therapy
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Cytomegalovirus Infections
Cytomegalovirus Cell-Mediated Immunity
Cytomegalovirus (CMV) is an important cause of illness and occasional deaths in infants who catch the virus before they are born, in newborns, and in children and adults who have weak immune systems.
- Trial name
- NCT00815165
- Where
- 2 sites in United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cytomegalovirus Infections
Cell-mediated Immunity for Prevention of CMV Disease
An open-label randomized controlled trial to adapt the duration of antiviral prophylaxis in D+/R- patients and in R+ patients receiving ATG according to the result of the T-Track® CMV assay.
- Trial name
- NCT02538172
- Testing
- T-Track® CMV assay
- Where
- 5 sites in Switzerland
- Volunteers
- 195 people
- Sponsor
- University of Lausanne Hospitals
Cytomegalovirus Infections, Hematopoietic Stem Cell Transplantation (HSCT)
CMV-CMI in csCMVi After HSCT
Cytomegalovirus (CMV) reactivation is a common and serious complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT), and the reconstitution of CMV-specific cell-mediated immunity (CMV-CMI) plays a key…
- Conditions
- Cytomegalovirus Infections, Hematopoietic Stem Cell Transplantation (HSCT), Immune Reconstitution
- Trial name
- NCT07688759
- Testing
- Anti-Cytomegalovirus Therapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Cytomegalovirus Cell Mediated Immunity, Stem Cell Transplantation, Hematopoietic
Impact of CMV-Specific Immune Reconstitution at the End of Letermovir Prophylaxis on the Development of Late Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant Recipients (INMUNOEND)
Cytomegalovirus (CMV) infection is a common complication in patients undergoing hematopoietic stem cell transplantation (SCT). Fixed-duration letermovir (LTV) prophylaxis during the first 100 days post-SCT is effective and safe…
- Trial name
- INMUNOEND (NCT06814301)
- Testing
- Periodic immunological monitoring of CMV-specific immune reconstitution will be performed using QTF-CMV
- Where
- Spain
- Volunteers
- 123 people
- Sponsor
- Maimónides Biomedical Research Institute of Córdoba
Renal Transplant Recipient, Immunized Against the Cytomegalovirus
Assessing the Risk of CMV Infection of the Renal Transplant About R + by Cellular Immunity Analyzed by the QuantiFERON ®-CMV Test.
Cytomegalovirus (CMV) infection was observed in over 30% of organ recipients with high morbidity. Moreover, no prophylaxis, 75% R + D-transplanted, 55%, R + D + and D-25% R + develop CMV.
- Trial name
- QUANTIC-R+ (NCT02064699)
- Testing
- CMV Infection
- Where
- 12 sites in France
- Volunteers
- 75 people
- Sponsor
- University Hospital, Limoges
Cytomegalovirus Viraemia
Cell Mediated Immunity for Secondary Prophylaxis in CMV SOT Patients
This study will evaluate whether a test for Cytomegalovirus (CMV) specific cell-mediated immunity can be used to determine whether patients who complete a course of therapy for CMV viremia need secondary antiviral prophylaxis.
- Trial name
- Q-CMV (NCT02370758)
- Testing
- Valganciclovir or Ganciclovir
- Where
- Canada
- Volunteers
- 32 people
- Sponsor
- University Health Network, Toronto
Cytomegalovirus Infection, GVHD
Clinical Validation of Lophius Biosciences Kit T-Track® CMV in Allo-HSCT Recipients
This study in a cohort of allo-HSCT recipients aims to validate the suitability of an improved T-Track® CMV assay to assess the functionality of CMV protein-reactive effector cells and its suitability to determine cut-off values…
- Trial name
- AlloProtectCMV (NCT02156479)
- Where
- Germany
- Volunteers
- 175 people
- Sponsor
- Lophius Biosciences GmbH
Quantiferon-CMV, Cytomegalovirus Infections
Anti-CMV Cellular Immunity Quantification Using an IGRA Test in Kidney Transplant récipients and Hemodialysis Patients, Comparison to Control Patients
Evaluation of anti-CMV T cellular immunity using an IGRA test (Quantiferon-CMV test) in kidney transplant recipients and hemodialysis patients, comparison to control patients.
- Conditions
- Quantiferon-CMV, Cytomegalovirus Infections, Kidney Transplant Infection, Hemodialysis
- Trial name
- Quantiferon (NCT03916497)
- Testing
- Quantiferon CMV
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Grenoble
Cytomegalovirus Viraemia
Cell-Mediated Immunity Based Primary Prophylaxis for CMV Infection in Organ Transplant Recipients
The study will prospectively determine the clinical utility of CMV cell-mediated immunity using the Quantiferon test. The investigators will use the assay results to tailor the duration of CMV prophylaxis in solid organ…
- Trial name
- QFT-CMV (NCT02784756)
- Testing
- Quantiferon-CMV assay
- Where
- 6 sites in Canada, Spain
- Volunteers
- 134 people
- Sponsor
- University Health Network, Toronto
Cytomegalovirus Cell Mediated Immunity, Hematopoietic Cell Transplant
The Use of Cytomegalovirus Cell Mediated Immunity to Optimize the Duration of Letermovir Prophylaxis in Hematopoietic Cell Transplant Recipients
The goal of this laboratory research study is to learn if interrupting a patient's letermovir dosing based on their immune system response can help HSC transplant patients avoid post-treatment CMV infections better than taking…
- Trial name
- NCT06639854
- Testing
- Hematopoietic Cell Transplant, Letermovir
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- M.D. Anderson Cancer Center
Renal Failure Chronic Requiring Dialysis
Validation of Lophius Kits T-Track® CMV and T-Track® EBV in Hemodialysis Patients
Cell-mediated immunity (CMI) and in particular T cells play a critical role in the rejection of transplanted organs. Thus, in transplant recipients a life-long and individualized immunosuppressive medication is required to avoid…
- Trial name
- NCT02630537
- Volunteers
- 133 people
- Sponsor
- Lophius Biosciences GmbH
Chronic Myeloproliferative Disorders, Leukemia
Measuring Changes in Blood in Patients at High Risk of Cytomegalovirus Infection After Undergoing Donor Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant
RATIONALE: Tests that measure certain changes in blood in patients at high risk of cytomegalovirus infection may help doctors learn more about predicting cytomegalovirus infection after donor stem cell transplant.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00716911
- Testing
- ganciclovir, polymerase chain reaction, flow cytometry
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Cytomegalovirus Infection
Immune Response and Cytomegalovirus in Intensive Care Unit (ICU) Patients
This prospective study evaluate the immune status of patients admitted in ICU.CMV remains dormant in the body, but in people with immune deficiency, CMV could reactivate and cause life-threatening pneumonia.
- Trial name
- 2006/25 (NCT00699868)
- Testing
- Sampling of blood, phenotypic analysis sub-populations NK by cytometric of stream in multiple markings
- Where
- France
- Volunteers
- 29 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Cytomegalovirus Viraemia, Stress, Physiological
Reactivation of CMV Infection in Immunocompetent Patients Under Severe Stress
Background. Human herpes viruses establish lifelong latency after primary infection and may reactivate in immunosuppressed patients causing significant morbidity and mortality.
- Conditions
- Cytomegalovirus Viraemia, Stress, Physiological, Receptor, Hormonal; Disorder, Other Deficiency of Cell-mediated Immunity
- Trial name
- RECYSTRESS (NCT01397058)
- Where
- Greece
- Volunteers
- 275 people
- Sponsor
- University of Athens
Awaiting Organ Transplant, Infection in Solid Organ Transplant Recipients
Cell Mediated Immunity With Risk of Cytomegalovirus (CMV) in Solid Organ Transplant Recipients
Cytomegalovirus (CMV) is a common infection with 60-90% of all adults worldwide having evidence of having the infection at sometime in their life.
- Trial name
- ViracorCMI (NCT01558037)
- Where
- United States
- Volunteers
- 113 people
- Sponsor
- Michael Ison
Arterial Occlusive Diseases, Atherosclerosis
Potential Role of CMV in Restenosis Following Angioplasty, in Atherosclerosis, and in Endothelial Dysfunction
The purpose of this study is to investigate whether the susceptibility of subjects to atherosclerosis is influenced by prior CMV exposure, whether the susceptability to endothelial dysfunction in patients with and in patients…
- Conditions
- Arterial Occlusive Diseases, Atherosclerosis, Coronary Disease, Cytomegalovirus Infections
- Trial name
- NCT00001531
- Where
- United States
- Volunteers
- 355 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Cytomegalovirus, Kidney Transplantation
Clinical Validation of Lophius Biosciences Kit T-Track® CMV in Kidney Transplant Recipients
This study aims to validate whether Lophius Biosciences Kit T-Track® CMV is suitable to assess the functionality of CMV-specific cell-mediated immunity (CMI) and to determine a protective cut-off value for CMV…
- Conditions
- Cytomegalovirus, Kidney Transplantation, CMV Specific Immune Response
- Trial name
- CMValue (NCT02083042)
- Where
- Germany
- Volunteers
- 97 people
- Sponsor
- Lophius Biosciences GmbH